On February 20, 2019 THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specialiazing in in vitro diagnostics and theranostics, reported its consolidated full-year revenues for 2018 and its cash position at December 31, 2018, figures which are currently being audited (Press release, Theradiag, FEB 20, 2019, View Source;utm_medium=rss&utm_campaign=theradiag-reports-annual-revenues-for-2018-and-its-year-end-cash-position [SID1234533518]).

In the year to December 31, 2018, Theradiag generated consolidated revenues of €8.9 million, from €9.0 million in 2017. Activity over the year was affected by the drop in theranostics revenues, which did not see exceptional orders in the first half of the year, whereas in the first half of 2017 revenues were boosted by strong activity levels following the signature of agreements with pharmaceutical companies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Thus 96% of theranostics revenues was generated by the sale of kits for routine use, which grew by 17% relative to 2017. Export sales of theranostic kits for routine use grew by 19%.

Revenues from IVD were stable, rising 1%.

"Despite the absence of non-recurrent sales in 2018, overall revenues were stable and the sales of LISA TRACKER kits for routine use continued to rise both in France and in export markets, with total growth of 17%. This reflects continued market penetration and the growing use of routine monitoring of patients, driven in particular by the development of biotherapies for chronic conditions. Over the year, Theradiag is likely to maintain the trends established and approach breakeven." commented Bertrand de Castelnau, CEO of Theradiag.

Cash position

At December 31, 2018 the Group had net cash of €3.4 million, compared to €5.2 million a year earlier.

Next press Release:

Full year earnings 2018: March 27, 2019

This date is given for indicative purposes and may be changed.

On February 20, 2019 Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, reported that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will participate in a fireside chat at the 8th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019, at 1:00 p.m. EST at the Lotte New York Palace Hotel (Press release, Heron Therapeutics, FEB 20, 2019, View Source [SID1234533544]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of this presentation will be available on the Company’s website at www.herontx.com in the Investor Resources section. A replay of the presentation will be archived on the site for 60 days.

On February 20, 2019 Alkermes plc (Nasdaq: ALKS) reported that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the SVB Leerink Global Healthcare Conference on Wednesday, Feb. 27, 2019 at 2:30 p.m. ET (7:30 p.m. BST) from New York, NY (Press release, Alkermes, FEB 20, 2019, View Source;p=irol-newsArticle&ID=2388210 [SID1234533543]). The audio portion of the fireside chat may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction, multiple sclerosis and oncology. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

On February 20, 2019 Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, reported it will report its fourth quarter and full year 2018 financial results and business progress on Wednesday, February 27, 2019, after the close of the U.S. financial markets (Press release, Tocagen, FEB 20, 2019, View Source;p=RssLanding&cat=news&id=2388299 [SID1234533540]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Additionally, Marty Duvall, chief executive officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Friday, March 1, at 9:30 a.m. ET in New York City.

The live audio webcast from the conference and subsequent replay may be accessed by visiting Tocagen’s website. The webcast will be available shortly after conclusion of the presentation and archived on the company’s website for 90 days following the presentation.

To receive Tocagen’s press releases and other investor information, please visit the Investor Relations page of the company’s website and register for email alerts.

On February 20, 2019 Agilent Technologies, Inc. (NYSE: A) reported revenue of $1.28 billion for the first quarter ended January 31, 2019, up 6 percent year over year (up 6 percent on a core basis(1)) (Press release, Agilent, FEB 20, 2019, https://www.agilent.com/about/newsroom/presrel/2019/20feb-gp19006.html [SID1234533539]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On a GAAP basis, first-quarter net income was $504 million or $1.57 per share, which included a discrete tax benefit of $299 million. This is compared to last year’s first-quarter net loss of $320 million or $0.99 net loss per share, which included a tax charge of $533 million related to U.S. Tax Reform legislation.

"We are pleased to start the year with a strong performance driving excellent revenue and EPS growth and exceeding our guidance," said Mike McMullen, Agilent president and CEO. "The Agilent team is delivering on our commitment to drive superior revenue and earnings growth."

"Our Agilent team continues to do a great job addressing customer needs across our business groups," continued McMullen. "We kicked off 2019 strengthening our best-in-class portfolio bringing new solutions and services to our customers to help them gain new insights and achieve greater productivity in their labs."

Financial Highlights

Life Sciences and Applied Markets Group

First-quarter revenue of $607 million from Agilent’s Life Sciences and Applied Markets Group (LSAG) grew 2 percent year over year (up 1 percent on a core basis(1)). Demand in the pharma, environmental and forensics markets led the results. LSAG’s operating margin for the quarter was 26.1 percent.

Agilent CrossLab Group

First-quarter revenue of $442 million from Agilent CrossLab Group (ACG) grew 8 percent year over year (up 10 percent on a core basis(1)). Growth was excellent across services and consumables, regions and end-markets. ACG’s operating margin for the quarter was 23.9 percent.

Diagnostics and Genomics Group

First-quarter revenue of $235 million from Agilent’s Diagnostics and Genomics Group (DGG) grew 13 percent year over year (up 12 percent on a core basis(1)). Strength in the pharma and clinical and diagnostics end-markets led an excellent performance. DGG’s operating margin for the quarter was 14.0 percent.

Second-Quarter and Full-Year Outlook

Agilent expects second-quarter 2019 revenue in the range of $1.255 billion to $1.270 billion. Second-quarter 2019 non-GAAP earnings are expected to be in the range of $0.70 to $0.72 per share(3).

For fiscal year 2019, the company is raising full-year revenue guidance to a range of $5.15 billion to $5.19 billion and non-GAAP earnings guidance to a range of $3.03 to $3.07 per share(3).

Conference Call

Agilent’s management will present more details about its first-quarter fiscal year 2019 financial results on a conference call with investors today at 1:30 p.m. (Pacific Time). This event will be webcast live in listen-only mode. Listeners may log on at www.investor.agilent.com and select "Q1 2019 Agilent Technologies Inc. Earnings Conference Call" in the "News & Events — Calendar of Events" section. The webcast will remain available on the company’s website for 90 days.

Additional information regarding financial results can be found at www.investor.agilent.com by selecting "Financial Results" in the "Financial Information" section.

A telephone replay of the conference call will be available at approximately February 20, 2019 at 4:30 PM (Pacific Time) after the call and through February 27 by dialing +1 855-859-2056 (or +1 404-537-3406 from outside the United States) and entering pass code 6738126.